X Huang1, Y Wang2, K Ren2. 1. Department of Pharmacology, Jilin Medical University, Jilin, China. E-mail: hxd1221@163.com. 2. Department of Pharmacology, Jilin Medical University, Jilin, China.
Abstract
Background: Alzheimer's disease (AD) is a sort of nerve degenerative disease with clinical manifestation of memory damage and cognitive dysfunction. Its typical pathological change is the abnormal deposition of amyloid-beta (Aβ). Method: In this study, a rat AD model with liquiritin (LQ) interference was established to observe the effects of LQ on the AD rats' behavioural memory and primary hippocampus cells. Results: Liquiritin had the effect of improving the rats' learning and memory ability, enhancing the activity of catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in rats' brain tissues, increasing the antioxidant ability, protecting the primary cultured hippocampal neurons and inhibiting the apoptosis induced by Aβ25-35. Conclusion: The protective effects of LQ can be related to the enhancement of antioxidase activity and clearance of oxygen radicals.
Background: Alzheimer's disease (AD) is a sort of nerve degenerative disease with clinical manifestation of memory damage and cognitive dysfunction. Its typical pathological change is the abnormal deposition of amyloid-beta (Aβ). Method: In this study, a ratAD model with liquiritin (LQ) interference was established to observe the effects of LQ on the ADrats' behavioural memory and primary hippocampus cells. Results:Liquiritin had the effect of improving the rats' learning and memory ability, enhancing the activity of catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in rats' brain tissues, increasing the antioxidant ability, protecting the primary cultured hippocampal neurons and inhibiting the apoptosis induced by Aβ25-35. Conclusion: The protective effects of LQ can be related to the enhancement of antioxidase activity and clearance of oxygen radicals.
Authors: Minerva Calvillo; Alfonso Diaz; Daniel I Limon; Miguel Angel Mayoral; María Elena Chánez-Cárdenas; Edgar Zenteno; Luis F Montaño; Jorge Guevara; Blanca Espinosa Journal: Neuropeptides Date: 2013-07-11 Impact factor: 3.286